STEPS Health System Outreach intervention for Chronic Kidney Disease (CKD)
System Interventions to Achieve Early and Equitable Transplants (STEPS) Study
See full descriptionAbout the trial for Chronic Kidney Disease (CKD)
Treatment Groups
This trial involves 2 different treatments. STEPS Health System Outreach Intervention is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether STEPS Health System Outreach intervention will improve 1 primary outcome and 12 secondary outcomes in patients with Chronic Kidney Disease (CKD). Measurement will happen over the course of 18 months.
Patient Q & A Section
What causes chronic kidney disease (ckd)?
The overall incidence and prevalence of CKD are increasing. Diabetes has become one of the most important risk factors for CKD. As diabetes persists in epidemic proportions, an urgent need exists to detect and treat CKD as soon as possible.
What is chronic kidney disease (ckd)?
Chronic kidney disease defines a substantial proportion of renal care expenditure in high-income countries, particularly in Canada, which is one of the largest medical systems in the world. Clinical and economic data from this study reveal considerable economic costs associated with chronic kidney disease, including higher hospital admission rates and higher costs of treatment.
What are the signs of chronic kidney disease (ckd)?
Symptoms of chronic kidney disease can include fatigue, feeling tired often, and feeling unwell on a daily basis. Many patients with chronic kidney disease also experience symptoms of headaches, shortness of breath, swelling in their back or leg muscles or pain during movement like walking or exercising. Kidney disease can also result in difficulty removing extra water and minerals such as sodium and phosphate during kidney dialysis treatment. Changes in the concentration of proteins like albumin and creatinine in the blood may also be a sign of chronic kidney disease. There are many ways to test for chronic kidney disease including blood tests, urine test and kidney ultrasounds.
Can chronic kidney disease (ckd) be cured?
The progression of CKD can be delayed to a certain extent by modifying certain risk factors, including proper weight management and the control of blood pressure. We should encourage our patients with CKD to keep up this routine to maintain good health and optimize their quality of life.
How many people get chronic kidney disease (ckd) a year in the United States?
3.6 million people have echolucent CKD in the United States. 7.1 percent of U.S. adults, and 5.2 percent of U.S. adults under the age of 18. 4.5 percent of men and 3.7 percent of women have echoluent or mildly elevated CKD or CKD. In the pediatric population, 1 percent of boys and 1.4 percent of girls have echoluent or mildly elevated CKD or CKD. 2.4 percent of these children have a history of CKD and 0.2 percent are diagnosed with CKD.
What are common treatments for chronic kidney disease (ckd)?
Patients with CKD receive therapies including: nutrition counseling to manage dietary protein imbalance; renal replacement therapy, including dialysis, peritoneal dialysis or renal transplantation; and medications to control blood pressure, hypertension, hypercholesterolemia, and osteoporosis.
Have there been other clinical trials involving steps health system outreach intervention?
A community organization (CA) can conduct clinical trials. The CA can engage key professionals working in a community with a population of end users who may not have access to clinical trials for a given medical condition.
How does steps health system outreach intervention work?
Stepwise system redesign has shown significant improvement in people's self-management and self-reported outcomes and an enhanced use of services resulting in reduced health care expenditure. A further evaluation is required to confirm any sustained effects.
Who should consider clinical trials for chronic kidney disease (ckd)?
Many CKD patients are reluctant to join clinical trials because of the unpleasant side effects of trial drugs. A review of the available literature and clinical experience indicated that the most important factors to consider are baseline risk and overall benefit at trial initiation, and not trial duration or type of drug.
Is steps health system outreach intervention typically used in combination with any other treatments?
Results from a recent clinical trial of this study show evidence that the combination of intensive case management with a usual care follow-up system resulted in a lower incidence of progression to ESRD and greater survival.
What is the primary cause of chronic kidney disease (ckd)?
Many factors can contribute to CKD progression including aging, gender, lifestyle and kidney diseases. In some cases, CKD may not be related to the causes of CKD like diabetes, chronic high blood pressure or a urinary tract infection.
What are the latest developments in steps health system outreach intervention for therapeutic use?
While there remains plenty of work to be done for the ultimate development of health technology, the evidence-based and cost-effective interventions for therapeutic use have increased dramatically, especially in the last 5 years.